The spread of COVID-19 has presented the global healthcare and life sciences sectors with unprecedented challenges. At the same time, it has underscored how quickly the industry can pivot to boost capacity in critical areas and support significant rapid changes in demand for technology and devices around the world.
As well as the immediate pressures on governments and healthcare services, COVID-19 has also unearthed important questions for the future of medical devices and technology. For instance, in years to come, which medical devices will be regarded as ‘critical’? How will this affect the supply chains of the companies producing these devices? What government regulations and requirements will exist for safeguarding domestic populations?
The opportunities and challenges that we discuss in this paper are designed to provide a rough guide to success in the medical technology space. At Alvarez & Marsal, we are leveraging our specialisms in operational transformation, transaction advisory and supply chain to guide leading enterprises through difficult times. We look forward to observing and contributing as the medical technology sector continues to develop.
Click here to read the article.
DHS Adds 43 Entities to the UFLPA Entity List — Enforcement Reach Extends Deep into Metals, Pharmaceuticals, and Food Supply Chains
August 6, 2026
On August 3, 2026, the Department of Homeland Security, as Chair of the Forced Labor Enforcement Task Force (FLETF), published an updated UFLPA Entity List adding 43 new entities (two of which appear on two separate sub-lists) and making technical corrections to two existing entries. The consolidated list now stands at 187 entities. Goods mined, produced, or manufactured, wholly or in part, by a listed entity are subject to the UFLPA's rebuttable presumption of forced labor and are prohibited from entry under 19 U.S.C. § 1307, effective immediately upon listing.
Financing Saudi Arabia’s Data Center Build-Out
August 6, 2026
Discover financing strategies for Saudi Arabia's data center build-out, from bankability and project finance to capital structuring and debt advisory.
Section 232 Pharmaceutical Duties: UK Rate Cut to Zero, and the Origin and Section 301 Questions That Follow
August 5, 2026
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.
Enterprise Management Incentive Plans - Recent Changes and Common Pitfalls
August 5, 2026
Enterprise Management Incentive (EMI) option plans have been at the centre of UK employee incentivisation for many years and remain popular with privately owned, fast-growing companies.
